title: Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.
abstract: Syndrome X, typified by obesity, insulin resistance (IR), dyslipidemia, and other metabolic abnormalities, is responsive to antidiabetic thiazolidinediones (TZDs). Peroxisome proliferator-activated receptor (PPAR) gamma, a target of TZDs, is expressed abundantly in adipocytes, suggesting an important role for this tissue in the etiology and treatment of IR. Targeted deletion of PPARgamma in adipose tissue resulted in marked adipocyte hypocellularity and hypertrophy, elevated levels of plasma free fatty acids and triglyceride, and decreased levels of plasma leptin and ACRP30. In addition, increased hepatic glucogenesis and IR were observed. Despite these defects, blood glucose, glucose and insulin tolerance, and insulin-stimulated muscle glucose uptake were all comparable to those of control mice. However, targeted mice were significantly more susceptible to high-fat diet-induced steatosis, hyperinsulinemia, and IR. Surprisingly, TZD treatment effectively reversed liver IR, whereas it failed to lower plasma free fatty acids. These results suggest that syndrome X may be comprised of separable PPARgamma-dependent components whose origins and therapeutic sites may reside in distinct tissues.
authors.affiliation: Departments of Medicine and Biology, University of California at San Diego, La Jolla, CA 92093, USA.
authors.forename: Weimin
authors.initials: W
authors.lastname: He
authors.forename: Yaacov
authors.initials: Y
authors.lastname: Barak
authors.forename: Andrea
authors.initials: A
authors.lastname: Hevener
authors.forename: Peter
authors.initials: P
authors.lastname: Olson
authors.forename: Debbie
authors.initials: D
authors.lastname: Liao
authors.forename: Jamie
authors.initials: J
authors.lastname: Le
authors.forename: Michael
authors.initials: M
authors.lastname: Nelson
authors.forename: Estelita
authors.initials: E
authors.lastname: Ong
authors.forename: Jerrold M
authors.initials: JM
authors.lastname: Olefsky
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Evans
mesh_terms: D017667:Adipocytes / Q000502:physiology; D052242:Adiponectin; D000273:Adipose Tissue / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007333:Insulin Resistance / Q000235:genetics*; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin / Q000097:blood; D008060:Lipodystrophy / Q000235:genetics; D008099:Liver / Q000187:drug effects / Q000502:physiology*; D008111:Liver Function Tests; D024821:Metabolic Syndrome / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D018482:Muscle, Skeletal / Q000187:drug effects / Q000502:physiology*; D009928:Organ Specificity; D011506:Proteins / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000172:deficiency* / Q000235:genetics*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology; D014157:Transcription Factors / Q000172:deficiency* / Q000235:genetics*
chemical_list: D052242:Adiponectin; D007004:Hypoglycemic Agents; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D011506:Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077154:Rosiglitazone